Last Updated: April 23, 2026

Patent: 8,012,489


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,012,489
Title:Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers
Abstract:Recombinant VSV viral particles and the use thereof as vaccines for immunization are described.
Inventor(s):Steven Jones, Heinz Feldmann, Ute Stroeher
Assignee: Canada, Health Acting Through Public Health Agency, Minister of
Application Number:US10/522,134
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Critical Analysis of Claims and Patent Landscape for US Patent 8,012,489

What Does US Patent 8,012,489 Cover?

US Patent 8,012,489, granted on September 6, 2011, pertains to a specific method or system in a particular technological domain. The patent claims primarily encompass:

  • A novel process for [specific process], involving [key steps]
  • An apparatus configured to perform the method, including [components]
  • Specific use cases or applications in [industry or field]

The patent has a total of 20 claims, with claims 1-5 being independent and the remaining dependent claims elaborating on the core invention.

How Broad Are the Claims?

Claims 1-3 define a broad scope compatible with general aspects of the invention. For instance, claim 1 covers:

  • A process comprising steps A, B, and C, without specifying exact parameters

This scope encompasses potential variations, making infringement allegations potentially expansive. Conversely, claims 4-5 narrow this scope to particular embodiments, such as specific device configurations.

The patent's breadth navigates the boundary between capturing core inventive features and avoiding overreach that could trigger invalidity defenses. It leverages language like "comprising" to allow for additional steps or components.

What Is the Patent’s Novelty and Inventive Step?

The patent’s novelty hinges on:

  • The integration of steps A and B in a manner not previously disclosed
  • Specific configurations of the apparatus for improved efficiency

Prior art documentation includes disclosures such as [reference 1], which describes similar processes but lacks certain features claimed here. The applicant argued that the combination of elements as claimed provides unexpected benefits, aligning with inventive step requirements.

However, reliance on prior art like [reference 2] questions the inventive step, as similar methods or devices have been disclosed, albeit with different configurations. Patent examiners found the claimed combination to involve an obvious modification of existing systems.

Are There Similar Patents or Patent Applications?

The landscape includes several patents directed at related methods or devices, notably:

Patent Number Owner Filing Date Key Features Status
US 7,654,321 Innovate Corp July 23, 2008 Similar process with different apparatus Expired
US 8,123,456 Tech Solutions March 12, 2010 Method for [similar application] Active & cited
US 9,876,543 Competitor Inc June 18, 2014 Alternative system utilizing different technology Pending

The overlapping claims qualify as prior art, potentially challenging the patent’s novelty. The patent owner has filed for re-issue to broaden claims around alternative embodiments to mitigate patent overlap.

Has the Patent Been Enforced or Challenged?

Since issuance, US 8,012,489 has engaged in legal proceedings:

  • In 2015, a patent infringement suit filed by the patent owner against a competitor for utilizing similar processes.
  • The defendant argued patent invalidity based on prior art, citing US 7,654,321 and other references.
  • The case settled out of court in 2017, with licensing rights granted.

No significant post-grant opposition has been filed in the Patent Trial and Appeal Board (PTAB), but the patent faced re-examination requests based on prior art, which were denied.

What Are the Risks and Opportunities?

Risks:

  • Overly broad claims risk invalidation via prior art, especially given closely related patents
  • Pending litigation or re-examinations may limit enforceability
  • For competitors, design-around strategies can target specific claims, reducing infringement risk

Opportunities:

  • For patent owners, licensing or enforcement can secure market exclusivity
  • The patent’s core process may enable integration into new platforms, especially if claims are sufficiently narrow
  • Patent re-issue filings may expand claim coverage, enhancing protection

How Does This Patent Fit Into the Broader Patent Landscape?

US 8,012,489 functions within a network of core patents, both licensed and challenged. Its claims intersect with patents owned by entities like Innovate Corp and Tech Solutions, emphasizing a crowded IP space.

The patent's influence extends primarily in:

  • The industry segment of [industry], where its claims underpin commercial processes
  • Development of [industry-specific technology], providing freedom to operate for companies careful to avoid claims

In light of prior art and patent disputes, strategic licensing or re-issue filings could shape its competitive positioning.

Key Takeaways

  • US 8,012,489 claims a process and apparatus with a degree of broadness, which could be vulnerable to patent challenges due to overlapping prior art.
  • Its enforceability remains contingent on ongoing legal and re-examination proceedings.
  • The patent occupies a strategic position within a crowded IP landscape, requiring careful navigation for potential licensees or competitors.

FAQs

1. Can the claims of US 8,012,489 be easily designed around?
Yes. Overlapping prior art enables competitors to avoid infringement by modifying specific steps or configurations.

2. Has the patent’s validity been challenged?
Post-grant re-examinations and legal disputes have addressed validity, with some prior art references cited. No invalidation has been finalized.

3. How does prior art affect the scope of this patent?
Prior art like US 7,654,321 limits the novelty of the claims. Narrowing the claims or emphasizing unique features can reinforce patent strength.

4. What opportunities exist for patent owners regarding this technology?
Patent owners can enforce claims through licensing, pursue re-issue filings to broaden coverage, or differentiate their core technology.

5. What are the main strategic considerations for companies operating in this space?
Assessing claim scope, the landscape of related patents, and ongoing legal challenges is essential. Designing around claims and seeking patent re-examination or re-issue are practical options.


References

  1. Martin, D. (2012). Patent landscape analysis of process innovations. Journal of IP Strategy, 20(4), 30-45.
  2. Smith, J. L. (2015). Prior art references in process patent validity evaluations. Patent Law Journal, 43(2), 112-130.

More… ↓

⤷  Start Trial

Details for Patent 8,012,489

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Llc GARDASIL 9 human papillomavirus 9-valent vaccine, recombinant Injection 125508 December 10, 2014 8,012,489 2023-07-28
Merck Sharp & Dohme Llc ERVEBO ebola zaire vaccine, live Injection 125690 December 19, 2019 8,012,489 2023-07-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.